Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

Deja, Stanisław; Porębska, Irena; Kowal, Aneta; Ząbek, Adam; Barg, Wojciech; Pawełczyk, Konrad; Stanimirova, I.; Daszykowski, M.; Korzeniewska, Anna; Jankowska, Renata; Młynarz, Piotr

doi:10.1016/j.jpba.2014.08.020

Cited by 88 publications

(79 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is substantiated by the rapid increase in studies over the last 5 years assessing metabolomic changes in COPD patients and animal models of disease [10][11][12][13][14][15][16][17]. These studies, however, lack a thorough analysis of metabolomic changes occurring in the lung tissue during the progression of emphysema.…”

Section: Discussionmentioning

confidence: 99%

“…To this end, there have been a number of studies published over the last few years assessing the COPD metabolome. This has included both untargeted [10][11][12][13] and targeted [14] metabolomics, as well as a combination of both [15] measured in either plasma or serum from COPD patients. In their combined approach, Bowler et al [15] reported a strong inverse association between the level of some plasma sphingomyelins (SMs) and emphysema in COPD patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics screening identifies reducedL-carnitine to be associated with progressive emphysema

et al. 2016

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis, small airway remodelling and emphysema. Emphysema is the destruction of alveolar structures, leading to enlarged airspaces and reduced surface area impairing the ability for gaseous exchange. To further understand the pathological mechanisms underlying progressive emphysema, we used MS-based approaches to quantify the lung, bronchoalveolar lavage fluid (BALF) and serum metabolome during emphysema progression in the established murine porcine pancreatic elastase (PPE) model on days 28, 56 and 161, compared with PBS controls. Partial least squares (PLS) analysis revealed greater changes in the metabolome of lung followed by BALF rather than serum during emphysema progression. Furthermore, we demonstrate for the first time that emphysema progression is associated with a reduction in lung-specific L-carnitine, a metabolite critical for transporting long-chain fatty acids into the mitochondria for their subsequent β-oxidation. In vitro, stimulation of the alveolar epithelial type II (ATII)-like LA4 cell line with L-carnitine diminished apoptosis induced by both PPE and H2O2. Moreover, PPE-treated mice demonstrated impaired lung function compared with PBS-treated controls (lung compliance; 0.067±0.008 ml/cmH20 compared with 0.035±0.005 ml/cmH20, P<0.0001), which improved following supplementation with L-carnitine (0.051±0.006, P<0.01) and was associated with a reduction in apoptosis. In summary, our results provide a new insight into the role of L-carnitine and, importantly, suggest therapeutic avenues for COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Metabolomics screening identifies reducedL-carnitine to be associated with progressive emphysema

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In another study, NMR-based serum metabolite profiles could distinguish chronic obstructive pulmonary disease and lung cancer. 98 And a study focused on the investigation of the effects of tumorigenesis and tumor growth on the noninvolved organs evaluated the metabolic phenotypes of multiple noninvolved mouse organ tissues such as heart, liver, spleen, lung, and kidney using a lung cancer xenograft model. 99 It is interesting to note that the noninvolved organs exhibit significant metabolic changes due to the tumor growth.…”

Section: Applicationsmentioning

confidence: 99%

Recent Advances in NMR-Based Metabolomics

Gowda¹,

Raftery

2016

Anal. Chem.

135

View full text Add to dashboard Cite

“…Metabolomics methods could be used to monitor changes of specific metabolism in process of tumor development, to predict tumor progression, to monitor tumor response to intervention, to determining a characteristic metabolic pattern for cancer patients, to identify tumor associated biomarkers and to provide helps for early diagnosis, prognosis evaluation and efficacy analysis for cancer patients. Metabolomics has been successfully applied to biomarkers screening for many cancers, such as bladder [10], colon [11], lung [12] and prostate cancers [13]. However, metabolomics studies on breast cancer is rarely reported.…”

Section: Introductionmentioning

confidence: 99%

Metabonomics studies on serum and urine of patients with breast cancer using 1H-NMR spectroscopy

Zhou¹,

Wang²,

Zhang³

2017

Oncotarget

View full text Add to dashboard Cite

The aim of this study was to describe a metabolomic study of breast cancer using 1 H-NMR combined with bioinformatics analysis. 1 H-NMR spectroscopy combined with multi-variate pattern recognition analysis was used to cluster the groups (serum and urine samples from breast cancer patients and healthy controls) and establish a breast-cancer-specific metabolites phenotype. Orthogonalpartial least-squares discriminant analysis (OPLS-DA) was capable of distinguishing serum and urine samples from breast cancer patients and healthy controls and establishing a breastcancer-specific metabolite profile. A total of 9 metabolites in serum concentration and 3 metabolites in urine concentration differed significantly between breast cancer patients and healthy controls. Serum samples from breast cancer patients were characterized by decreased concentrations of choline, glucose, histidine, valine, lysine, acetate, tyrosine and glutamic, accompanied by increased concentrations of lipid relative to healthy controls. In urine samples, the level of phenylacetylglycine and guanidoacetate was significantly lower, while the level of citrate was significantly higher in breast cancer patients relative to healthy controls. In conclusion, this study reveals the metabolic profile of serum and urine from breast cancer patients. NMRbased metabolomics has the potential to be developed into a novel clinical tool for diagnosis or therapeutic monitoring for breast cancer. However, because of limitations of methods and technique, further research and verification is needed.

show abstract

Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

Cited by 88 publications

References 65 publications

Metabolomics screening identifies reducedL-carnitine to be associated with progressive emphysema

Metabolomics screening identifies reducedL-carnitine to be associated with progressive emphysema

Recent Advances in NMR-Based Metabolomics

Metabonomics studies on serum and urine of patients with breast cancer using 1H-NMR spectroscopy

Contact Info

Product

Resources

About